|
Indications and Dosage
Oral
Allergic rhinitis Adult: For relief of symptoms of seasonal or perennial cases with or without allergic conjunctivitis: Usual dose: 10 mg once daily. In case of severe symptoms, may increase to 20 mg once daily. Child: >12 years Same as adult dose. Oral Chronic idiopathic urticaria Adult: 10 mg once daily.
Child: >12 years Same as adult dose. |
|
What are the brands available for Ebastine in Philippines?
|
|
Other Known Brands
|
|
Hepatic Impairment
Severe: Max: 10 mg daily.
|
|
Administration
Ebastine May be taken with or without food.
|
|
Special Precautions
Patient with conditions that may prolong QT interval (e.g. congenital long QT syndrome, hypokalaemia, hypomagnesaemia, receiving drugs known to cause QT prolongation). Severe hepatic impairment. Children. Pregnancy and lactation.
|
|
Adverse Reactions
Cardiac disorders: Rarely, palpitations, tachycardia.
Gastrointestinal disorders: Dry mouth. Rarely, dysgeusia, abdominal pain, vomiting, nausea, dyspepsia. General disorders and administration site conditions: Rarely, oedema, asthenia. Hepatobiliary disorders: Rarely, hepatitis, cholestasis. Immune system disorders: Hypersensitivity reactions (e.g. angioedema, anaphylaxis). Investigations: Rarely, increased transaminases, GGT, alkaline phosphatase and bilirubin. Nervous system disorders: Headache, somnolence. Rarely, dizziness, hypoaesthesia. Psychiatric disorders: Rarely, insomnia, nervousness. Reproductive system and breast disorders: Rarely, menstrual disorders. Skin and subcutaneous tissue disorders: Rarely, rash, dermatitis, urticaria. |
|
Drug Interactions
Increased plasma concentration with ketoconazole, itraconazole, and erythromycin. Reduced plasma concentration and antihistamine effect with rifampicin.
|
|
Lab Interference
May suppress the wheal and flare reactions to skin test antigens for up to 5-7 days after discontinuation.
|
|
Action
Description:
Mechanism of Action: Ebastine, a piperidine derivative, is a long-acting, non-sedating antihistamine that competes with histamine on H1 receptors of peripheral vasculature. Onset: Suppression of skin and wheal flare: 1-3 hours. Duration: Suppression of skin and wheal flare: >24 hours. Pharmacokinetics: Absorption: Rapidly absorbed. Time to peak plasma concentration: 2-4 hours (carebastine). Distribution: Crosses the placenta (carebastine); enters breast milk (ebastine and carebastine). Volume of distribution: 90-143 L (carebastine). Plasma protein binding: >95%. Metabolism: Undergoes extensive first-pass metabolism in the intestine, and in the liver by CYP3A4 and CYP2J2 isoenzymes; almost completely converted into the active metabolite, carebastine. Excretion: Via urine (66%, mainly as conjugated metabolites). Elimination half-life: 10-26 hours (carebastine). |
|
Chemical Structure
 Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 3191, Ebastine. https://pubchem.ncbi.nlm.nih.gov/compound/Ebastine. Accessed Mar. 28, 2025. |
|
Storage
Store below 30°C.
|
|
MIMS Class
|
|
ATC Classification
R06AX22 - ebastine ; Belongs to the class of other antihistamines for systemic use.
|
|
References
Brayfield A, Cadart C (eds). Ebastine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/02/2025. Ebastine. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 11/02/2025. Kestine 10 mg Film-coated Tablet (Zuellig Pharma Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 11/02/2025. Kestine 20 mg Film-coated Tablet (Zuellig Pharma Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 11/02/2025.
|
Sign up for Free to continue reading
Continue with Google
Sign up with email
Already a member?
Sign in
Sign Out
